Cancer Control Generates $82.9B in Economic Value
A WifOR Institute analysis across 56 Commonwealth countries measures the economic return on cancer control investment.
Updated on Nov. 5, 2026 in Cancer
Live Poll
Should your government spend more on cancer prevention and treatment?
WifOR Institute estimated that cancer control investments generated USD 82.9 billion in gross value added in 2022. The findings were part of an analysis tied to The Lancet Oncology Commission on Cancer in the Commonwealth.
Why it matters
Limited healthcare resources make it necessary to understand the value of cancer control in both health and economic terms. The findings show that cancer spending can return measurable economic activity, particularly in lower-income Commonwealth countries.
The estimate comes from multi-regional input-output modeling across all 56 Commonwealth countries, which measured economic activity through the health economy, adjacent supply-chain sectors and induced consumption. Some country-level expenditure figures were estimated from GDP per capita and cancer incidence because direct data was unavailable.
The players
WifOR Institute
A Darmstadt, Germany-based research institute that originated as a spin-off from the Technical University of Darmstadt and conducts economic impact analyses worldwide.
The Lancet Oncology Commission on Cancer in the Commonwealth
An expert commission that examines cancer burden and funding needs across Commonwealth countries and publishes its findings in The Lancet Oncology.
The details
The analysis, conducted by WifOR Institute, measured how cancer control spending flows through health systems, supply chains and household consumption. It builds on a 2025 publication by WifOR Institute and Harvard University in eClinicalMedicine.
Timeline
2014: Baseline subsector data used before extrapolation.
2022: Year to which the USD 82.9 billion estimate applies.
2025: Prior WifOR and Harvard study published in eClinicalMedicine.
Health Landscape
The analysis extends the Lancet Oncology Commission's examination of cancer burden in Commonwealth countries by quantifying the economic return on cancer control spending. It adds an economic lens to a debate that has largely focused on clinical outcomes and funding gaps.
Cancer control investment supports screening, treatment and prevention programs that affect access to care in many countries. The findings suggest such spending may also strengthen local economies in lower-income settings.
The takeaway
Investment in cancer control can generate measurable economic activity alongside health benefits. Policymakers weighing limited healthcare budgets may find these returns relevant to funding decisions.
Further reading
Explore more on Cancer to see how treatment investment and disease burden are tracked globally.
More information
Read the full Lancet Oncology Commission on Cancer in the Commonwealth publication00396-7) for the underlying cancer burden analysis.
Source note: This article includes information reported by Informationdienst Wissenschaft e.V. - idw.
Live Poll
Should your government spend more on cancer prevention and treatment?
